Using Tissue Cell Culture To Make A Protein Or Polypeptide Patents (Class 435/70.1)
-
Patent number: 12077796Abstract: The present invention relates to the use of limited amounts of cysteine and tryptophan in the cell culture medium during production of recombinant proteins, and in particular antibodies. Proteins and antibodies produced under such controlled conditions exhibit reduced heterogeneity, in particular reduced charge variants heterogeneity.Type: GrantFiled: May 29, 2018Date of Patent: September 3, 2024Assignee: UCB BIOPHARMA SRLInventors: Bassem Ben Yahia, Laetitia Malphettes, Nadine Kochanowski, Gill Renner, Sandrine Durran, Andrew Jeffrey Yates
-
Patent number: 12043845Abstract: The invention provide a method for reducing the amount of acidic species and/or increasing the amount of basic species in a composition comprising a recombinant protein or for increasing the specific production rate of mammalian cells expressing a recombinant protein to simplify subsequent clarification and purification of the recombinant protein, said method comprising culturing mammalian cells expressing said recombinant protein in a cell culture medium comprising citrulline.Type: GrantFiled: June 8, 2018Date of Patent: July 23, 2024Assignee: Polpharma Biologics S.A.Inventors: Louis Boon, Lenneke De Winter, Tomasz Sitar
-
Patent number: 11974552Abstract: A mouse model that develops type 1 diabetes spontaneously and used thereof are described. In some embodiments, the mouse model expresses a combination of HLA-DQ8 and GAD65 in a C57BL/6-BTBR congenic background, where the GAD65 is expressed under the rat insulin promoter.Type: GrantFiled: August 2, 2019Date of Patent: May 7, 2024Assignee: The University of ToledoInventors: Shahnawaz Imam, Maria Alfonso-Jaume, Juan Carlos Jaume
-
Patent number: 11913961Abstract: The present invention generally relates to method for preparing a biological sample for use in an immunolabeling process. The invention also relates to corresponding kits for use in the immunolabeling process.Type: GrantFiled: January 18, 2016Date of Patent: February 27, 2024Assignee: B KROMNIGONInventors: Per Fogelstrand, Ulf Yrlid
-
Patent number: 11788062Abstract: Compositions and methods are described herein for transdifferentiation of multipotent stromal cells into cells that can express insulin.Type: GrantFiled: October 4, 2017Date of Patent: October 17, 2023Assignee: BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGEInventors: Mandi J. Lopez, Wei Duan
-
Patent number: 11674125Abstract: This disclosure relates to glycoengineering, and methods of utilizing glycoengineering for various therapeutic purposes.Type: GrantFiled: December 17, 2018Date of Patent: June 13, 2023Assignee: The General Hospital CorporationInventors: Robert M. Anthony, Maya Kitaoka
-
Patent number: 11229669Abstract: The presently disclosed subject matter provides methods and compositions for enhancing the immune response toward cancers and pathogens. It relates to novel designs of T cell receptors (TCRs) and engineered immunoresponsive cells comprising the same. The novel TCR binds to an antigen in an HLA-independent manner. In certain embodiments, the novel TCR provides enhanced sensitivity for a target gene having a low expression level.Type: GrantFiled: October 20, 2020Date of Patent: January 25, 2022Assignee: MEMORIAL SLOAN-KETTERING CANCER CENTERInventors: Michel Sadelain, Jorge A. Mansilla-Soto, Justin Eyquem, Anton Dobrin
-
Patent number: 11203739Abstract: Disclosed herein are compositions, systems, and methods for modulating proliferation, differentiation and pluripotency of cells.Type: GrantFiled: April 7, 2015Date of Patent: December 21, 2021Assignees: Memorial Sloan-Kettering Cancer Center, The Rockefeller UniversityInventors: Lydia W. S. Finley, Bryce W. Carey, Craig B. Thompson, C. David Allis
-
Patent number: 10752668Abstract: The invention relates to the regulated expression of a chimeric antigen receptor (CAR) within a lentiviral vector. The CAR comprises a hook-binding domain that interacts with a hook, preferably encoded by the same lentiviral vector, which prevents proper processing and release of the CAR to the cell membrane. The invention encompasses vectors, methods of making the vectors, and methods of using them, including medicinal uses. The vectors can be used for administration to humans to induce immune responses and to treat cancers and tumors.Type: GrantFiled: July 24, 2015Date of Patent: August 25, 2020Assignees: Theravectys, Institut Curie, Centre National de la Recherche Scientifique, Sorbonne Universite, Institut National de la Sante et de la Recherche Medicale (INSERM)Inventors: Sophie Agaugue, Lorenzo Tibaldi, Klervi Even-Desrumaux, Dmitry Trubetskoy, Franck Perez, Sebastian Amigorena, Cécile Bauche
-
Patent number: 10571371Abstract: The disclosure provides improved materials and methods for optically clearing biological tissue that is subsequently used for deep tissue imaging analysis. Also provided is a description of a microscopic image acquisition methodology in which imagery of intact tissues are acquired to rapidly acquire microscopy data on a whole-organ scale to maximize cost effectiveness for biological microscopy and minimize time spent performing such analysis.Type: GrantFiled: August 7, 2015Date of Patent: February 25, 2020Assignee: WAKE FOREST UNIVERSITY HEALTH SCIENCESInventors: Frank Marini, George Christ
-
Patent number: 10017739Abstract: Provided herein are methods of expanding B cells, and in particularly B10 cells capable of producing IL-10, ex vivo. The methods include incubation of harvested B cells in the presence of IL-21. Compositions comprising the ex vivo expanded B cells and methods of using the expanded B cell-containing compositions to treat diseases or conditions are also provided. Methods of assessing B10 cell function in a subject are also provided.Type: GrantFiled: March 12, 2013Date of Patent: July 10, 2018Assignee: DUKE UNIVERSITYInventors: Thomas F. Tedder, Ayumi Yoshizaki, Tomomitsu Miyagaki, Evgueni Kountikov, Jonathan C. Poe
-
Patent number: 9931360Abstract: A method of treating liver-based inborn, metabolic deficiencies is disclosed by treatment of an individual, such as a patient suffering from liver-based inborn, metabolic deficiencies, with human progenitor or stem cells, a cell population or their progeny. The cells used in the treatment have the following characteristics. They are positive for vimentin, ?-smooth muscle actin (ASMA), and for at least one mesenchymal marker such as CD90, CD29, CD73, and CD44. They are positive for at least one hepatocyte marker such as albumin, alpha-fetoprotein, alpha-1 antitrypsin, HNF-4 and MRP2 transporter. They express at least one hepatocyte-like property or function such as G6P, CYP1B1, CYP3A4, TDO, TAT, GS, GGT, CK8, and EAAT2. They are negative for at least one marker such as cytokeratin-19, CD45, CD34, CD49f, CD133, HLA-DR, and CD117. They have mesenchymal-like morphology. They originate from human adult liver cells.Type: GrantFiled: August 25, 2017Date of Patent: April 3, 2018Assignee: UNIVERSITE CATHOLIQUE DE LOUVAINInventors: Etienne Sokal, Mustapha Najimi
-
Patent number: 9603921Abstract: The present invention provides a virosome comprising a virosomal membrane comprising at least one lipid and envelope proteins of an enveloped virus and of the virosome and attached to said envelope proteins. Furthermore, the invention provides a vaccine comprising the virosome of the invention and, a method for the production of a virosome of the invention. Moreover, the invention provides a use of a virosome of the invention for the preparation of a vaccine, e.g. for the prevention or alleviation of a disease related to an HBV infection, and a method for the vaccination of a subject.Type: GrantFiled: October 20, 2005Date of Patent: March 28, 2017Assignee: Janssen Vaccines AGInventors: Christian Moser, Giovanna Assero, Epifanio Fichera, Dario Ventura, Laurence Lempereur, Diana Felnerova
-
Patent number: 9534025Abstract: Polypeptide having activity inducing pathogen plant defence, nucleotide sequence encodes it, microorganism, compositions and methods. The polypeptide is a subtilisin derived from a strain of Acremonium strictum. The polypeptide is encoded by the nucleotide sequence SEQ ID NO: 1 or sequences at least 90% homologous to the same and has the amino acid sequence SEQ ID NO: 2 or sequences at least 90% homologous to the same.Type: GrantFiled: May 23, 2016Date of Patent: January 3, 2017Assignees: UNIVERSIDAD NACIONAL DE TUCUMAN, CONSEJO NACIONAL DE INVESTIGACIONES CIENTIFICAS Y TECNICAS (CONICET)Inventors: Atilio Pedro Castagnaro, Juan Carlos Diaz Ricci, Nadia Regina Chalfoun, Josefina Racedo, Sergio Miguel Salazar
-
Patent number: 9150660Abstract: The invention relates to human targets of interest (TOI), anti-TOI ligands, kits compositions and method.Type: GrantFiled: March 23, 2015Date of Patent: October 6, 2015Assignee: Kymab LimitedInventor: Jasper Rupert Clube
-
Patent number: 9139648Abstract: The invention relates to human targets of interest (TOI), anti-TOI ligands, kits compositions and method.Type: GrantFiled: March 23, 2015Date of Patent: September 22, 2015Assignee: Kymab LimitedInventor: Jasper Rupert Clube
-
Patent number: 9040020Abstract: The present invention relates to novel muteins derived from human lipocalin 2 (hNGAL) and related proteins that bind a given non-natural ligand with detectable affinity. The invention also related to corresponding nucleic acid molecules encoding such a mutein and to a method for their generation. The invention further relates to a method for producing such a mutein. Furthermore, the invention is directed to a pharmaceutical composition comprising such a lipocalin mutein as well as to various uses of the mutein.Type: GrantFiled: April 9, 2013Date of Patent: May 26, 2015Assignee: Technische Universitaet MuenchenInventors: Arne Skerra, Andreas Eichinger, Hyun-Jin Kim
-
Patent number: 9034628Abstract: Described herein is a composition useful for inducing expression of genes whose expression is under control of an inducible promoter sequence and methods for the compositions preparation and use.Type: GrantFiled: February 17, 2011Date of Patent: May 19, 2015Assignee: Danisco US Inc.Inventors: George R. England, Aaron Kelley, Colin Mitchinson
-
Patent number: 9023620Abstract: The present invention relates to enzyme preparations consisting essentially of an enzyme which has cellulytic activity, which perform very well in industrial applications such as laundry compositions, for biopolishing of newly manufactured textiles, for providing an abraded look of cellulosic fabric or garment, and for treatment of paper pulp. Further, the invention relates to DNA constructs encoding such enzymes, a method for providing a gene encoding for such enzymes, a method of producing the enzymes, enzyme preparations containing such enzymes, and the use of these enzymes for a number of industrial applications.Type: GrantFiled: November 21, 2012Date of Patent: May 5, 2015Assignee: Novozymes A/SInventors: Martin Schulein, Lene Nonboe Andersen, Soren Flensted Lassen, Markus Sakari Kauppinen, Lene Lange, Ruby Ilum Nielsen, Shinobu Takagi, Michiko Ihara
-
Patent number: 9017968Abstract: The present invention is concerned with an engineered biological system for production of authentic human basic fibroblast growth factor (hbFGF). The system makes use of a bacterial host and has a recombinant DNA construct with an insert. The insert contains a first VegC promoter, lacq operator, a second VegC promoter and DNA coding for human basic fibroblast growth factor.Type: GrantFiled: November 9, 2012Date of Patent: April 28, 2015Assignee: Gene-Vinate LimitedInventor: Wan Keung Raymond Wong
-
Patent number: 9017987Abstract: The invention relates to a method of producing an influenza virus H5 polypeptide in a plant comprising the steps of cloning an influenza H5 gene or nucleic acid encoding its functional equivalent into a vector adapted to target components present in the plant, infiltrating at least a portion of the plant with the vector or transforming plant tissue with the vector so as to transiently express the influenza virus H5 polypeptide, and/or to create a transgenic plant; and recover the influenza virus H5 polypeptide expressed by the plant. The invention further relates to vectors, transgenic plants or parts thereof and the progeny of such plants used in or which come about as a result of the method.Type: GrantFiled: January 29, 2013Date of Patent: April 28, 2015Assignee: University of Cape TownInventors: Anna-Lise Williamson, Edward Peter Rybicki, James Malcolm Maclean, Inga Isabel Becker-Hitzeroth
-
Patent number: 9012180Abstract: An improved system for large scale production of polypeptides in cell culture is provided. In accordance with the present invention, cells expressing a polypeptide of interest are grown in media that contain copper, glutamate or both. The use of such a system allows production of polypeptides in which misfolding and/or aggregation are reduced, and in which total glycosylation is increased. Polypeptides expressed in accordance with the present invention may be advantageously used in the preparation of pharmaceutical, agricultural or other commercial compositions.Type: GrantFiled: February 29, 2008Date of Patent: April 21, 2015Assignee: Wyeth LLCInventors: Denis Drapeau, Jessica Snow, Gregory Hiller, Yen Tung Luan
-
Patent number: 8999666Abstract: The invention relates to kinase ligands and polyligands. In particular, the invention relates to ligands, homopolyligands, and heteropolyligands that modulate PKC activity. The ligands and polyligands are utilized as research tools or as therapeutics. The invention includes linkage of the ligands, homopolyligands, and heteropolyligands to a cellular localization signal, epitope tag and/or a reporter. The invention also includes polynucleotides encoding the ligands and polyligands.Type: GrantFiled: August 9, 2007Date of Patent: April 7, 2015Assignee: Intrexon CorporationInventors: Thomas D. Reed, Amy H. Atzel
-
Patent number: 8993731Abstract: A humanized agonistic antibody which binds human PD-1 comprising a heavy chain wherein the variable domain of the heavy chain comprises the sequence given in SEQ ID NO:1 for CDR-H1, the sequence given in SEQ ID NO: 2 for CDR-H2 and the sequence given in SEQ ID NO: 3 for CDR-H3 and the heavy chain framework region is derived from human sub-group sequence VH4 3-1 4-30.4+JH4 (SEQ ID NO: 33). The disclosure also extends to therapeutic uses of the antibody molecules, compositions and methods for producing said antibody molecules.Type: GrantFiled: March 9, 2011Date of Patent: March 31, 2015Assignee: UCB Biopharma SPRLInventor: Kerry Louise Tyson
-
Patent number: 8993263Abstract: The invention relates to kinase ligands and polyligands. In particular, the invention relates to ligands, homopolyligands, and heteropolyligands that modulate PKA activity. The ligands and polyligands are utilized as research tools or as therapeutics. The invention includes linkage of the ligands, homopolyligands, and heteropolyligands to a cellular localization signal, epitope tag and/or a reporter. The invention also includes polynucleotides encoding the ligands and polyligands.Type: GrantFiled: August 7, 2007Date of Patent: March 31, 2015Assignee: Intrexon CorporationInventor: Thomas D. Reed
-
Patent number: 8993299Abstract: The present invention relates to polypeptides having cellobiohydrolase I activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.Type: GrantFiled: October 28, 2013Date of Patent: March 31, 2015Assignee: Novozymes A/SInventors: Lene Lange, Wenping Wu, Dominique Aubert, Sara Landvik, Kirk Matthew Schnorr, Ib Groth Clausen
-
Patent number: 8993742Abstract: The invention relates to polarized cell tubulo-vesicular structure localization signals. The localization signals are utilized as research tools or are linked to polypeptides of interest or therapeutic molecules. Disclosed are methods of making and using polypeptides and modified polypeptides as signals to localize therapeutics, experimental compounds, peptides, proteins and/or other macromolecules to the tubulo-vesicular structures of polarized cells. The polypeptides of the invention optionally include linkage to reporters, epitopes and/or other experimental or therapeutic molecules. The invention also encompasses polynucleotides encoding the localization signals and vectors comprising these polynucleotides.Type: GrantFiled: December 20, 2010Date of Patent: March 31, 2015Assignee: Intrexon CorporationInventor: Thomas David Reed
-
Patent number: 8986997Abstract: The present invention relates to methods and compositions for enhancing folding and stability of biological molecules. In particular, the present invention relates to methods and compositions for identifying biological molecules with enhanced stability. The present invention further relates to host cells that confer enhanced stability to biological molecules expressed therein.Type: GrantFiled: August 27, 2008Date of Patent: March 24, 2015Assignee: The Regents of the University of MichiganInventors: James Bardwell, Linda Foit, Ajamaluddin Malik, Tobias Baumann, Maximilian Kern
-
Patent number: 8986969Abstract: The present invention relates to polypeptides having cellobiohydrolase I activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.Type: GrantFiled: October 28, 2013Date of Patent: March 24, 2015Assignee: Novozymes A/SInventors: Lene Lange, Wenping Wu, Dominique Aubert, Sara Landvik, Kirk Matthew Schnorr, Ib Groth Clausen
-
Patent number: 8980579Abstract: Provided herein are methods for stable integration and/or expression of one or more recombinant polynucleotides in a host cell. The recombinant polynucleotides are typically integrated into the host genome at some native chromosomal integration sites. The integration can be mediated by homologous recombination or by using a hybrid recombinase targeting the specific chromosomal locations. The native chromosomal integration sites in the host cells, which support stable integration and strong transcription activities of foreign genes, are present within or adjacent to specific genes in the CHO genome, the ankyrin 2 gene (Ank2), cleavage and polydenylation specific factor 4 gene (Cpsf4), C-Mos gene, and Nephrocystin-1/Mal gene. Also provided are methods and nucleic acid molecules for inserting site-specific recombination sequences (chromosomal landing pads) into these specific chromosomal locations, engineered host cells containing chromosomal landing pads, methods and compositions (e.g., kits) therefore.Type: GrantFiled: April 5, 2012Date of Patent: March 17, 2015Assignee: The Scripps Research InstituteInventors: Vincent P. Mauro, Wei Zhou, Bruce Cunningham, Gerald M. Edelman
-
Patent number: 8980626Abstract: Antibody expression vectors and plasmids can incorporate various antibody gene portions for transcription of the antibody DNA and expression of the antibody in an appropriate host cell. The expression vectors and plasmids have restriction enzyme sites that facilitate ligation of antibody-encoding DNA into the vectors. The vectors incorporate enhancer and promoter sequences that can be varied to interact with transcription factors in the host cell and thereby control transcription of the antibody-encoding DNA. A kit can incorporate these vectors and plasmids.Type: GrantFiled: January 24, 2014Date of Patent: March 17, 2015Assignee: Janssen Biotech, Inc.Inventors: Jill Carton, Jin Lu, Bernard Scallon, Linda Snyder
-
Patent number: 8975391Abstract: The invention concerns novel regulatory elements as well as related vectors and cells. Furthermore, it relates to methods of improving expression of polypeptides from nucleic acids such as cloned genes and to the production of various polypeptides in host cells using said novel regulatory elements. Additionally, the invention relates to uses of said novel regulatory elements as insulators, in gene therapy or for improving host cell lines.Type: GrantFiled: February 22, 2013Date of Patent: March 10, 2015Assignee: Boehringer Ingelheim Pharma GmbH & Co. KGInventor: Barbara Enenkel
-
Patent number: 8969043Abstract: Biopharmaceutical process development with recombinant protein producing mammalian cells has realized a tremendous increase in both productivity and product yields in the past years. These achievements can be mainly attributed to the advancements in cell line development, media, and process optimization. Only recently, genome-scale technologies enable a system-level analysis to elucidate the complex biomolecular basis of protein production in mammalian cells promising an increased process understanding and the deduction of knowledge-based approaches for further process optimization. The present invention describes a method for a rational cell culturing process using such a knowledge-based approach.Type: GrantFiled: May 27, 2010Date of Patent: March 3, 2015Assignee: Boehringer Ingelheim International GmbHInventors: Jochen Schaub, Torsten Schulz
-
Patent number: 8962277Abstract: The invention refers to a method of producing a recombinant polypeptide of interest (POI) in a cell culture, comprising genetically engineering a eukaryotic cell line—to specifically cause prolongation of the G2+M cell cycle phase in a pre-culture phase, and—to produce the POI in a producing phase following the pre-culture phase, a high producer cell line and cell culture as well as a method of increasing the yield of a recombinant POI production in a cell culture.Type: GrantFiled: July 4, 2011Date of Patent: February 24, 2015Assignee: Univeristät für Bodenkultur WienInventors: Diethard Mattanovich, Martin Dragosits, Brigitte Gasser, Michael Maurer, Michael Sauer
-
Patent number: 8961995Abstract: The present invention provides alphavirus replicons and methods of their use in producing heterologous protein.Type: GrantFiled: March 7, 2013Date of Patent: February 24, 2015Assignee: UAB Research FoundationInventors: Ilya Frolov, Elena Frolova
-
Patent number: 8956830Abstract: Polypeptide preparations having target levels of glycans, and methods of producing such polypeptide preparations using DMSO, are described.Type: GrantFiled: March 14, 2013Date of Patent: February 17, 2015Assignee: Momenta Pharmaceuticals, Inc.Inventors: Holly Prentice, Rasheed Tijani, Brett Belongia
-
Patent number: 8957015Abstract: The invention provides isolated nucleic acid and amino acid sequences of novel human tumor suppressors, antibodies to such tumor suppressors, methods of detecting such nucleic acids and proteins, methods of screening for modulators of tumor suppressors, and methods of diagnosing and treating tumors with such nucleic acids and proteins.Type: GrantFiled: April 8, 2013Date of Patent: February 17, 2015Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Curtis C. Harris, Makoto Nagashima
-
Patent number: 8951755Abstract: The use of VHHs in the preparation of products to provide stability of antibody specificity under destabilizing conditions whereby normally lower eukaryotes or traditional antibodies are killed or inactivated.Type: GrantFiled: March 12, 1999Date of Patent: February 10, 2015Assignee: BAC IP B.V.Inventors: Daniel Convents, Leo G. Frenken, Michael M. Harmsen, Richard H. van der Linden, Cornelis T. Verrips
-
Patent number: 8951790Abstract: The present invention relates to the construction and utilization of a new mammalian expression vector that contains a unique multiple cloning site (MCS), designated pUHAB. The pUHAB vector comprises a high copy replication origin (ColE1), a drug resistance gene (TK-Hygromycin), and a human cytomegalovirus promoter operably associated with a unique intron (hCMV/intron). Further, pUHAB comprises a selectable marker conferring resistance to kanamycin in bacterial cells, and a phage f1(+) region. pUHAB can be used to transiently or stably express cloned genes when transfected into mammalian cells. The invention also encompasses kits and host cells and cell lines comprising pUHAB, and methods of producing a recombinant protein using pUHAB.Type: GrantFiled: January 6, 2012Date of Patent: February 10, 2015Assignee: Merck Sharp & Dohme Corp.Inventor: Deba P. Saha
-
Patent number: 8945867Abstract: The present invention relates to a process for producing a desired polypeptide using rat cells. Specifically, the present invention relates to a process for producing the polypeptide which comprises culturing rat cells such as YB2/3HL.P2.G11.16Ag.20 (hereinafter referred to as YB2/0), preferably rat cells to which a recombinant DNA comprising DNA encoding a desired polypeptide such as an immunologically functional molecule is introduced, in a medium which does not contain serum (hereinafter referred to as a serum-free medium). Among the desired polypeptides obtained by the process of the present invention, an antibody obtained by using a transformant of YB2/0 has a high antibody-dependent cell-mediated cytotoxic activity (hereinafter sometimes referred to as ADCC activity) and is useful as a pharmaceutical agent.Type: GrantFiled: February 2, 2009Date of Patent: February 3, 2015Assignee: Kyowa Hakko Kirin Co., Ltd.Inventors: Tatsuya Ogawa, Yoshinobu Konno, Naohisa Akashi, Hiroshi Takasugi, Seiji Sugimoto, Keiichi Yano
-
Patent number: 8945878Abstract: The invention relates to novel polypeptides and cells comprising the polypeptides. The polypeptides and cells are used in methods to identify and/or isolate cells producing a protein with specific biological functions. In particular, the methods may be used for identifying, selecting, and isolating cells producing antigen-specific monoclonal antibodies.Type: GrantFiled: September 6, 2013Date of Patent: February 3, 2015Assignee: OncoMed Pharmaceuticals, Inc.Inventors: Austin L. Gurney, Alexandra L. L. Lazetic, Christopher J. Bond
-
Patent number: 8945530Abstract: The present invention relates to the provision of a DNA sequence of the major grass pollen allergen Lol p 4. The invention also encompasses fragments, new combinations of partial sequences and point mutants having a hypoallergenic action. The recombinant DNA molecules and the derived polypeptides, fragments, new combinations of partial sequences and variants can be utilised for the therapy of pollen-allergic diseases. The proteins prepared by recombinant methods can be employed for in vitro and in vivo diagnosis of pollen allergies.Type: GrantFiled: December 6, 2010Date of Patent: February 3, 2015Assignee: Merck Patent GmbHInventors: Andreas Nandy, Helmut Fiebig, Oliver Cromwell
-
Patent number: 8945874Abstract: The present invention relates to compositions and methods for characterizing, diagnosing, and treating cancer. In particular the invention provides the means and methods for the diagnosis, characterization, prognosis and treatment of cancer and specifically targeting cancer stem cells. The present invention provides an antibody that specifically binds to a non-ligand binding membrane proximal region of the extracellular domain of a human Notch receptor and inhibits tumor growth. The present invention further provides a method of treating cancer, the method comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding membrane proximal region of the extracellular domain of a human Notch receptor protein and inhibits tumor growth.Type: GrantFiled: March 13, 2013Date of Patent: February 3, 2015Assignee: OncoMed Pharmaceuticals, Inc.Inventors: Austin L. Gurney, Timothy Charles Hoey, Maureen Fitch Bruhns, Fumiko Takada Axelrod
-
Patent number: 8945873Abstract: The present invention relates to Notch-binding agents and Notch antagonists and methods of using the agents and/or antagonists for treating diseases such as cancer. The present invention provides antibodies that specifically bind to a non-ligand binding region of the extracellular domain of one or more human Notch receptor, such as Notch2 and/or Notch3, and inhibit tumor growth. The present invention further provides methods of treating cancer, the methods comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human Notch receptor protein and inhibits tumor growth.Type: GrantFiled: March 1, 2013Date of Patent: February 3, 2015Assignee: OncoMed Pharmaceuticals, Inc.Inventors: Austin L. Gurney, Timothy Charles Hoey, Edward Thein Htun van der Horst, Aaron Ken Sato, Yuan Ching Liu, Maureen Fitch Bruhns, John A. Lewicki
-
Patent number: 8945857Abstract: The invention provides methods for isolating cells, particularly antibody-secreting cells that have a high likelihood of secreting antibodies specific for a desired antigen for the purpose of making monoclonal antibodies.Type: GrantFiled: June 30, 2006Date of Patent: February 3, 2015Inventor: John Schrader
-
Patent number: 8945870Abstract: An object of the present invention is to provide a monoclonal antibody which is useful for treating or diagnosing a disease relating to system ASC amino acid transporter 2 (hereinafter, referred to as “ASCT2”) or a method using the antibody. The present invention provides a monoclonal antibody which specifically recognizes a native three-dimensional structure of an extracellular region of ASCT2 and binds to the extracellular region, or an antibody fragment thereof; a hybridoma which produces the antibody; a DNA which encodes the antibody; a vector which contains the DNA; a transformant obtainable by introducing the vector; a process for producing an antibody or an antibody fragment thereof using the hybridoma or the transformant; and a therapeutic agent using the antibody or the antibody fragment thereof, and a diagnostic agent using the antibody or the antibody fragment thereof.Type: GrantFiled: August 13, 2012Date of Patent: February 3, 2015Assignee: Kyowa Hakko Kirin Co., LtdInventors: Norihiko Shiraishi, Akiko Furuya, Hiroe Toki, Hiroshi Ando, Masayo Suzuki, Tsuguo Kubota
-
Patent number: 8945547Abstract: The present invention relates to compositions and methods for characterizing, diagnosing, and treating cancer. In particular the invention provides the means and methods for the diagnosis, characterization, prognosis and treatment of cancer and specifically targeting cancer stem cells. The present invention provides an antibody that specifically binds to a non-ligand binding membrane proximal region of the extracellular domain of a human Notch receptor and inhibits tumor growth. The present invention further provides a method of treating cancer, the method comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding membrane proximal region of the extracellular domain of a human Notch receptor protein and inhibits tumor growth.Type: GrantFiled: March 14, 2013Date of Patent: February 3, 2015Assignee: OncoMed Pharmaceuticals, Inc.Inventors: Austin L. Gurney, Timothy Charles Hoey, Maureen Fitch Bruhns, Fumiko Takada Axelrod
-
Patent number: 8937169Abstract: Human G-protein chemokine receptor polypeptides and DNA (RNA) encoding such polypeptides and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptides for identifying antagonists and agonists to such polypeptides and methods of using the agonists and antagonists therapeutically to treat conditions related to the underexpression and overexpression of the G-protein chemokine receptor polypeptides, respectively. Also disclosed are diagnostic methods for detecting a mutation in the G-protein chemokine receptor nucleic acid sequences and detecting a level of the soluble form of the receptors in a sample derived from a host.Type: GrantFiled: January 31, 2011Date of Patent: January 20, 2015Assignee: Human Genome Sciences, Inc.Inventor: Yi Li
-
Publication number: 20150017687Abstract: Provided is a method for producing glycoprotein with a specific glycoform compostion. The desired glycoform profile is brought about Iby altering the culture conditions on the basis of IVCC rather than the age of the culture. Further, the method renders a high product yield.Type: ApplicationFiled: January 17, 2013Publication date: January 15, 2015Inventors: Asma Ahmed, Rekha Hariharan, Sama Naresh Babu
-
Patent number: 8927269Abstract: The present invention provides an Avian adeno-associated virus (AAAV) virus and vectors and particles derived therefrom. In addition, the present invention provides methods of delivering a nucleic acid to a cell using the AAAV vectors and particles. Methods of isolating the AAAV are provided.Type: GrantFiled: May 18, 2004Date of Patent: January 6, 2015Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Ioannis Bossis, John A. Chiorini